Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

Claim 1. (Currently amended). A pharmaceutical composition suitable for topical administration, ~~or a dietary supplement~~ comprising at least 5% (w/w) of a triterpene fraction obtained from Butyrospermum parkii comprising:

- at least 2% (w/w) lupeol;

- at least 2% (w/w) α-amyrin and/or β-amyrin; and

- at least 2% (w/w) butyrospermol,~~;~~

wherein said triterpenes, lupeol, α-amyrin, β-amyrin and/or butyrospermol, may be in the form of free alcohols or esters thereof.~~;~~

~~and wherein said lupeol or said butyrospermol is in a weight percentage in the composition ranging from 5-90%.~~

Claim 2. (Currently amended). The pharmaceutical composition ~~or a dietary supplement~~ according to claim 1, wherein said triterpene fraction comprises:

- 10-40% (w/w) lupeol;

- 10-40% (w/w) α-amyrin and/or β-amyrin; and

- 10-40% (w/w) butyrospermol,

wherein said triterpenes, lupeol, α-amyrin, β-amyrin and/or butyrospermol, may be in the form of free alcohols or esters thereof.

Claim 3. (Currently amended). The pharmaceutical composition ~~or dietary supplement~~ according to claim 1, further comprising a sterol fraction comprising at least one sterol

selected from the group consisting of stigmasterol, avanasterol, 24-methyl-cholest-7-enol, karitesterol A, karitesterol B and α-spinasterol, wherein said sterols may be in the form of free alcohols or esters thereof.

Claim 4. (Currently amended). The pharmaceutical composition ~~or dietary supplement~~ according to claim 1, wherein the triterpene fraction is in a weight percentage of at most 100% (w/w).

Claim 5. (Currently amended). The pharmaceutical composition ~~or dietary supplement~~ according to claim 3, wherein the ratio between the triterpene fraction and the sterol fraction is in the range of 1:100 to 500:1 (w/w).

Claim 6. (Currently amended). The pharmaceutical composition ~~or dietary supplement~~ according to claim 1, further comprising an extract of Calendula officinalis.

Claims 7-8. (Cancelled).

Claim 9. (Currently amended). The pharmaceutical composition according to claim 1 ~~claim 8~~, wherein the pharmaceutical composition is formulated as a fluid, ointment, gel, liniment, emulsion or spray (e.g. aerosol).

Claim 10. (Withdrawn). The use of a composition according to claim 1 for the preparation of a medicament or a dietary supplement for immunomodulation in a mammal.

Claim 11. (Withdrawn). The use of a composition claim 1 for the preparation of a medicament or a dietary supplement for the suppression of hypersensitivity and/or inflammatory reaction in a mammal.

Claim 12. (Withdrawn). The use of a composition according to claim 11 for the preparation of a medicament for the treatment or prevention of inflammation or hypersensitivity of the skin or mucous membranes in a mammal.

Claim 13. (Withdrawn). The use according to claim 11 for the preparation of a medicament or a dietary supplement for the treatment or prevention of autoimmune disease and/or chronic inflammatory disease in a mammal.

Claim 14. (Withdrawn). The use according to claim 13 for the preparation of a medicament or a dietary supplement for the treatment or prevention of psoriasis, atopic dermatitis, contact dermatitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis or osteoarthritis in a mammal.

Claim 15. (Withdrawn). The use of a composition according to claim 1 for the preparation of a medicament or a dietary supplement for the alleviation of pain in a mammal.

Claim 16. (Withdrawn). The use of a composition according to claim 1 for the preparation of a medicament or a dietary supplement for the treatment or prevention of prostatitis and/or benign prostatic hypertrophy.

Claim 17. (Currently amended). A method for treating psoriasis, atopic dermatitis or contact dermatitis ~~hypersensitivity or inflammation~~ in a mammal, comprising topically administering a composition comprising at least 5% (w/w) of a triterpene fraction obtained from Butyrospermum parkii, wherein the triterpene fraction comprises:

- at least 2% (w/w) lupeol;

- at least 2% (w/w) α-amyrin and/or β-amyrin; and

- at least 2% (w/w) butyrospermol;

wherein said triterpenes, lupeol, α-amyrin, β-amyrin and/or butyrospermol, may be in the form of free alcohols or esters thereof.

Claim 18. (Cancelled).

Claim 19. (Withdrawn). A method for the treatment or prevention of an autoimmune disorder and/or a chronic inflammatory disorder in a mammal, characterised by administering a mixture according to claim 1 to said mammal.

Claim 20. (Withdrawn). A method for the treatment or prevention of psoriasis, atopic eczema, contact dermatitis, Crohn's disease, ulcerative colitis, rheumatoid arthritis and/or osteoarthritis in a mammal, characterised by administering a mixture according to claim 1 to said mammal.

Claim 21. (Withdrawn). A method for the treatment or prevention of pain in a mammal, characterised by administering a mixture according to claim 1 to said mammal.

Claim 22. (Withdrawn). A method for the treatment or prevention of prostatitis or benign prostatic hypertrophy in a mammal, characterised by administering a mixture according to claim 1 to said mammal.

Claim 23. (Withdrawn). A method for the preparation of a composition according to claim 1, characterised by obtaining an extract or a concentrate of *Butyrospermum parkii*, said extract or concentrate containing at least 5% (w/w) of a Butyrospermum-triterpene fraction comprising:

- at least 2% (w/w) lupeol;

- at least 2% (w/w) α-amyrin and/or β-amyrin;

- at least 2% (w/w) butyrospermol; and

- optionally at least 1% germanicol, dammaradienol, 24-methylene-dammarenol and/or parkeol,

wherein said triterpenes may be in the form of free alcohols or esters thereof, especially cinnamic acid, acetic acid or fatty acid esters; and

Claim 24. (Withdrawn). A method according to claim 23 wherein the extract or concentrate of Butyrospermum parkii further comprises a sterol fraction comprising at least one sterol selected from the group consisting of stigmasterol, avanasterol, 24-methyl-cholest-7-enol, karitesterol A, karitesterol B and α-spinasterol, wherein said sterols may be in the form of free alcohols or esters thereof, especially cinnamic acid, acetic acid or fatty acid esters.

Claim 25. (Withdrawn). A method according to claim 23 wherein said extract or concentrate of Butyrospermum parkii is further mixed with a pharmaceutically acceptable carrier.

Claim 26. (Currently amended). The pharmaceutical composition ~~or dietary supplement~~ according to claim 1, further comprising a pharmaceutically acceptable carrier.

Claim 27. (Currently amended). The pharmaceutical composition ~~or dietary supplement~~ according to claim 1, further comprising at least 1% (w/w) of a fraction comprising at least one chemical selected from the group consisting of germanicol, dammaradienol, 24-methylene-dammarenol and parkeol.

Claim 28. (Currently amended). The pharmaceutical composition ~~or dietary supplement~~ according to claim 1, wherein said esters are selected from the group consisting ~~consisiting~~ of cinnamic acid esters, acetic acid esters and fatty acid esters.

Claim 29. (Currently amended). The pharmaceutical composition ~~or dietary supplement~~ according to claim 2, further comprising 2-30% (w/w) of a fraction comprising at least one chemical selected from the group consisting of germanicol, dammaradienol, 24-methylene-dammarenol and parkeol.

Claim 30. (Currently amended). The pharmaceutical composition ~~or dietary supplement~~ according to claim 3, wherein said esters are selected from the group consisting of cinnamic acid esters, acetic acid esters and fatty acid esters.

Claim 31. (Currently amended). The pharmaceutical composition ~~or dietary supplement~~ according to claim 3, wherein the triterpene fraction together with the sterol fraction is in a weight percentage of at most 100% (w/w).

Claim 32. (Currently amended). The pharmaceutical composition ~~or dietary supplement~~ according to claim 1, wherein the triterpene fraction is derived from the fruit, leaves, stem, bark or root of Butyrospermum parkii.

Claim 33. (Currently amended). The pharmaceutical composition ~~or dietary supplement~~ according to claim 32, wherein the triterpene fraction is derived from the fruit of Butyrospermum parkii.

Claim 34. (Currently amended). The method according to claim 17, wherein said triterpene fraction is in a composition as defined in any one of claims 1 to 6, 9, 26 to 33, and 35 to 40.

Claim 35. (Currently amended). The pharmaceutical composition ~~or dietary supplement~~ according to claim 1, wherein said butyrospermol is in a weight percentage in the composition ranging from 8-40 %.

Claim 36. (Currently amended). The pharmaceutical composition ~~or dietary supplement~~ according to claim 1, wherein said butyrospermol is in a weight percentage in the composition ranging from 9-40 %.

Claim 37. (Currently amended). The pharmaceutical composition ~~or dietary supplement~~ according to claim 1, wherein said lupeol is in a weight percentage in the composition ranging from 7-40 %.

Claim 38. (Currently amended). The pharmaceutical composition ~~or dietary supplement~~ according to claim 1, wherein said lupeol is in a weight percentage in the composition ranging from 8-40 %.

Claim 39. (New). The pharmaceutical composition according to claim 1, wherein said lupeol is in a weight percentage in the composition ranging from 5-90 %.

Claim 40. (New). The pharmaceutical composition according to claim 1, comprising at least 10% (w/w) of said triterpene fraction obtained from Butyrospermum parkii.